News Mylan challenges Amgen's Neulasta in US Mylan and Biocon file biosimilar of white blood cell booster
News EU drug regulators concerned about Brexit impact European regulators concerned over impact of EMA move.
News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News J&J to "price responsibly", says CEO post Trump meeting Gorsky promises "transparency report" on pricing.
News As rituximab biosimilars close in, Roche showcases Gazyva su... Roche faces competition against its blockbuster haematology drug
News How will Trump presidency affect biosimilars in US? Trump makes vague promise to "reform" FDA - but how?
News BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
